Allison Avrich Ciesla

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

Ruth Link‐Gelles, Allison Avrich Ciesla, Katherine E. Fleming-Dutra et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 185 citations · Full text

Booster Formulation, Immunodeficiencies, Immunology +19

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

Ruth Link‐Gelles, Allison Avrich Ciesla, Josephine Mak et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 159 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +23

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023

Ruth Link‐Gelles, Allison Avrich Ciesla, Lauren E. Roper et al. · MMWR Morbidity and Mortality Weekly Report · 2023 · 143 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +19

Adolescent Outcomes of Children With Early Speech Sound Disorders With and Without Language Impairment

Barbara Lewis, Lisa Freebairn, Jessica Tag et al. · American Journal of Speech-Language Pathology · 2015 · 113 citations · Full text

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis

Amanda B. Payne, Janet A. Watts, Patrick K. Mitchell et al. · The Lancet · 2024 · 78 citations

Vaccination, Vaccine Safety, Vaccinology +14